List of Excipients in Branded Drug SUBLOCADE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Indivior Inc	SUBLOCADE	buprenorphine	12496-0100	METHYLPYRROLIDONE
Indivior Inc	SUBLOCADE	buprenorphine	12496-0100	POLY(DL-LACTIC-CO-GLYCOLIC ACID)

Sublocade Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Sublocade is a monthly or bimonthly extended-release buprenorphine injection built around Indivior’s ATRIGEL delivery system. Its commercial value depends less on the buprenorphine molecule than on the excipient-polymer matrix, depot formation, injection performance, release kinetics, and manufacturing controls. The strongest opportunities are in biodegradable polymers, solvent systems, depot injectability, packaging, analytical testing, and alternative long-acting delivery platforms.

What excipients are used in Sublocade?

Sublocade contains buprenorphine, poly(DL-lactide-co-glycolide), or PLG, and N-methyl-2-pyrrolidone, commonly abbreviated NMP. The product is supplied as a prefilled syringe containing a liquid polymer solution that forms a solid or semisolid depot after subcutaneous injection.[1]

Component	Function in Sublocade	Commercial relevance
Buprenorphine	Partial opioid agonist active ingredient	Established opioid-use-disorder therapy
PLG	Biodegradable depot-forming polymer	Controls drug release and depot persistence
NMP	Water-miscible solvent and polymer vehicle	Controls injection viscosity, phase inversion, and depot formation
Prefilled syringe and needle	Dose delivery and handling system	Influences usability, administration errors, and supply-chain cost

Sublocade is available in 100-mg and 300-mg doses. The 300-mg dose is generally used during initiation or when clinically indicated, while the 100-mg dose is used for maintenance in many patients.[1]

The formulation is administered subcutaneously by a healthcare professional. It is not designed for intravenous, intramuscular, or intradermal administration. The label requires trained administration because the depot can be large, firm, and persistent after injection.[1]

How does the ATRIGEL excipient system create a long-acting depot?

ATRIGEL is a solvent-exchange depot system. The formulation is injected as a polymer solution. After exposure to physiological fluid, NMP diffuses outward and water enters the depot. PLG precipitates or solidifies, trapping buprenorphine and creating a drug-releasing matrix.[2]

The excipient strategy must balance several competing properties:

1. Low enough viscosity for delivery through a practical needle.
2. Sufficient polymer concentration to produce a durable depot.
3. Controlled solvent exchange after injection.
4. Predictable buprenorphine diffusion and polymer erosion.
5. Acceptable local tissue response.
6. Chemical stability during refrigerated storage.
7. Reproducible depot formation across patients and injection sites.

This combination gives the formulation its commercial defensibility. A competitor cannot readily substitute a different polymer or solvent without re-establishing release kinetics, local tolerability, depot dimensions, syringeability, and clinical performance.

Why PLG is commercially important

PLG is widely used in biodegradable drug-delivery products, but its performance depends on molecular weight, lactide-to-glycolide ratio, end-group chemistry, particle contamination, residual monomer, water content, and manufacturing history.

Small changes in PLG can alter:

• Depot formation time
• Initial drug release
• Duration of release
• Polymer erosion
• Local inflammation
• Syringe force
• Needle requirements
• Long-term storage stability

For excipient suppliers, this creates an opportunity to sell qualified polymer grades rather than commodity PLG. The relevant competitive advantage is consistency at pharmaceutical scale, supported by a drug-master-file or equivalent regulatory package.

Why NMP is commercially important

NMP functions as the vehicle and phase-inversion solvent. It affects viscosity, drug solubility, polymer solubility, water exchange, and depot morphology.

NMP is commercially attractive because it is established in injectable delivery systems, but it also creates regulatory and formulation constraints. A substitute solvent would need to match NMP’s polymer-solubilizing capacity and in vivo phase behavior. Solvent replacement is therefore a high-value opportunity with a high development burden.

Potential alternatives include other water-miscible polar aprotic solvents, but each candidate would require evaluation for:

• Local toxicity
• Injection pain
• Tissue irritation
• Polymer compatibility
• Drug precipitation
• Residual solvent limits
• Stability
• Extractables and leachables
• Regulatory acceptability

A solvent that improves tolerability or allows a smaller injection volume could have material commercial value, but it would likely require a new formulation-development and clinical strategy.

What formulations are protected by Sublocade’s patent estate?

Sublocade protection is centered on the extended-release injectable formulation, the biodegradable depot technology, composition parameters, manufacturing methods, and use of the depot for opioid-use-disorder treatment. The primary intellectual-property value is not simple coverage of buprenorphine.

The relevant protection categories include:

Protection category	Covered subject matter	Competitive implication
Depot composition	Buprenorphine in a biodegradable polymer-solvent system	Direct formulation competition
Polymer parameters	PLG composition, concentration, molecular weight, or related characteristics	Limits substitution with similar matrices
Solvent system	Solvent-polymer combinations and phase-inversion behavior	Raises reformulation costs
Release profile	Extended release over approximately one month or longer	Supports clinical differentiation
Administration	Subcutaneous delivery by healthcare professionals	Limits dosage-form replication
Manufacturing	Mixing, filling, sterilization, and control processes	Creates CMC barriers
Method of use	Treatment of opioid-use disorder and dosing regimens	May affect generic labeling and litigation
Device and packaging	Prefilled syringe, needle, and product presentation	Creates secondary lifecycle protection

The exact patent scope depends on issued claims, terminal disclaimers, patent-term adjustments, Orange Book listings, and any later regulatory submissions. FDA’s Orange Book should be used as the controlling source for current listed patents and pediatric exclusivity status.[3]

When does Sublocade lose exclusivity?

Sublocade received FDA approval on November 30, 2017, under NDA 209819.[1] Its regulatory exclusivity and patent protection operate on different timelines.

Event	Date or status
FDA approval	November 30, 2017
NDA	209819
Active ingredient	Buprenorphine
Dosage form	Extended-release subcutaneous injection
Core regulatory issue	New long-acting formulation of an established active ingredient
Three-year exclusivity	Generally associated with approval of new clinical investigations essential to approval
Patent protection	Depends on listed formulation, method, and delivery-system patents
Generic pathway	Potential 505(j) ANDA pathway, subject to product-specific requirements
Biosimilar pathway	Not applicable because Sublocade is not a biologic

Sublocade did not receive biologic exclusivity. It is a small-molecule drug product. A generic applicant would need to address the formulation, depot behavior, delivery system, and clinical or pharmacokinetic requirements established by FDA.

Patent expiration dates should be evaluated patent by patent. Formulation and depot patents can extend well beyond the three-year regulatory exclusivity period, while method-of-use patents may create additional litigation exposure if a proposed generic label omits the protected indication or dosing language.

What is the Orange Book status of Sublocade?

Sublocade is listed in the FDA Orange Book as an NDA product. Its Orange Book position matters because listed patents can support a Paragraph IV certification and trigger patent litigation under the Hatch-Waxman framework.[3]

For a generic applicant, the principal risks are:

• Paragraph IV certification against formulation or delivery-system patents.
• A 30-month stay if the NDA holder files timely litigation.
• Difficulty demonstrating pharmaceutical equivalence for a complex depot.
• Potential need for comparative pharmacokinetic or clinical data.
• Device and prefilled-syringe requirements.
• Labeling restrictions involving opioid-use-disorder treatment.
• Manufacturing-site qualification for a sterile injectable product.

An ANDA applicant may attempt a section viii statement or a skinny label for method-of-use patents. That approach is less useful where the core listed patents cover the formulation or dosage form itself.

What generic entry risks exist for Sublocade?

Generic entry is more difficult than for an immediate-release buprenorphine tablet or film. Sublocade combines a drug substance with a controlled-release injectable matrix and a specialized administration process.

Technical barriers

The most significant technical barriers are:

• Matching the in vivo release profile.
• Controlling initial release and depot formation.
• Demonstrating equivalent exposure over the full dosing interval.
• Reproducing syringeability at commercial scale.
• Maintaining sterility and particulate control.
• Controlling PLG molecular-weight distribution.
• Matching residual NMP and water content.
• Establishing consistent injection-site tolerability.

A generic product could theoretically use a different excipient system, but that approach would likely move the product away from a conventional ANDA strategy. A materially different depot system could require a new drug application or substantial clinical development.

Commercial barriers

The product is administered by healthcare professionals, which reduces pharmacy substitution and creates a provider-account relationship. A generic entrant would need:

• A dependable sterile injectable supply chain.
• Trained administration support.
• Payer coverage.
• Patient access programs.
• Provider confidence in depot performance.
• A strategy for managing adverse-event reporting and injection-site issues.

These barriers favor a limited number of technically capable entrants rather than broad commodity-generic competition.

Which excipient opportunities are most attractive?

1. Qualified PLG supply

The clearest opportunity is high-quality PLG designed for injectable depot products. Suppliers can differentiate through:

• Narrow molecular-weight distribution.
• Lot-to-lot consistency.
• Controlled lactide:glycolide ratios.
• Low endotoxin and particulate levels.
• Low residual monomer.
• Defined degradation behavior.
• Regulatory documentation.
• Dual-source manufacturing.

A supplier that becomes embedded in a long-acting injectable platform can obtain significant switching costs, even if the underlying polymer is not independently patent-protected.

2. Solvent replacement

A lower-irritation solvent or solvent blend could support:

• Reduced injection pain.
• Lower injection volume.
• Faster depot formation.
• Improved drug loading.
• Longer storage stability.
• Better compatibility with new polymers.

The commercial opportunity is large, but solvent replacement is technically demanding. The candidate must reproduce the ATRIGEL-type phase transition while maintaining acceptable tissue exposure.

3. Higher-concentration depot formulations

A formulation that delivers the same monthly dose in a smaller volume could improve clinical handling. Sublocade’s injection volume and post-injection depot are relevant usability considerations.

Potential strategies include:

• Higher buprenorphine loading.
• More efficient polymer precipitation.
• Lower-viscosity polymer solutions.
• In situ microparticle formation.
• Polymer blends with faster solvent exchange.
• Alternative biodegradable matrices.

Any such change must preserve dose uniformity and avoid an excessive initial release.

4. Longer-interval delivery

A three-month or six-month buprenorphine depot could create a differentiated commercial product. Longer intervals may improve persistence in treatment and reduce administration frequency.

The technical challenge is maintaining therapeutic concentrations without:

• Early dose dumping.
• Prolonged subtherapeutic exposure.
• Difficult depot removal.
• Excessive local tissue reaction.
• Accumulation after repeated dosing.

Longer-interval products would likely receive composition, dosing-regimen, and method-of-use protection independent of existing monthly products.

5. Injection-device improvements

Device and packaging innovations can support lifecycle management without changing the active ingredient. Opportunities include:

• Lower-force syringes.
• Needle systems optimized for viscous formulations.
• Integrated needle shields.
• Improved temperature controls.
• Tamper-evident packaging.
• Administration aids for abdominal subcutaneous injection.
• Digital documentation of dose administration.

Device changes may produce commercial value even where formulation changes are limited.

How does Sublocade compare with competing buprenorphine products?

Product category	Administration	Excipient opportunity	Competitive position
Sublocade	Monthly or bimonthly subcutaneous injection	PLG/NMP depot, syringe, polymer alternatives	Long-acting office-based treatment
Buprenorphine sublingual film	Daily transmucosal dosing	Mucoadhesive polymers, taste masking, film processing	Lower formulation complexity, higher daily adherence burden
Buprenorphine sublingual tablet	Daily transmucosal dosing	Compression aids, disintegration agents, taste masking	Low-cost generic competition
Buprenorphine implant	Long-duration subdermal implant	Implant polymer and insertion system	Procedural delivery and different manufacturing profile
Other long-acting injections	Monthly or longer injection	Microparticles, in situ depots, lipid systems	Potential platform competition

Sublocade’s differentiation is the combination of long duration, healthcare-provider administration, and reduced daily handling. Its formulation complexity also protects it from immediate substitution by standard buprenorphine generics.

What manufacturing and IP barriers affect commercial entry?

Manufacturing is a central barrier because the product is a sterile, viscous, polymer-containing injectable. Critical process parameters may include:

• Polymer dissolution time.
• Mixing temperature.
• Shear exposure.
• Drug dispersion.
• Water control.
• Filling accuracy.
• Syringe compatibility.
• Sterilization strategy.
• Container-closure integrity.
• In-process viscosity.
• Particle and endotoxin limits.

A supplier seeking entry should pursue freedom-to-operate analysis across three layers:

1. ATRIGEL-like formulation claims.
2. PLG/NMP composition and processing claims.
3. Device, syringe, packaging, and administration claims.

Patent risk is highest for products that reproduce the same active concentration, polymer-solvent system, injection route, and release profile. A distinct excipient system may reduce literal infringement risk but increase FDA development requirements.

What licensing opportunities exist around Sublocade-type technology?

Commercial licensing opportunities are concentrated in platform technologies rather than in buprenorphine itself.

Potential deal structures include:

• Polymer supply agreements with exclusivity or volume commitments.
• Licenses for alternative solvent systems.
• Co-development of higher-loading depots.
• Regional rights for long-acting opioid-use-disorder products.
• Device licensing for viscous injectable formulations.
• Contract development and manufacturing agreements.
• Access to analytical methods for depot release testing.
• Licensing of polymer characterization and scale-up processes.

Indivior’s ATRIGEL technology is strategically valuable because it can support multiple injectable products. A licensee would typically seek rights to a defined therapeutic area, geographic territory, or formulation class rather than unrestricted platform access.

How strong is the Sublocade patent estate?

The estate is commercially meaningful because it protects a complex product architecture rather than only a conventional active ingredient. Its strength is highest where claims cover the formulation itself and where a competing product would need to reproduce the same polymer-solvent depot mechanism.

Strength factors include:

• A specialized biodegradable depot.
• Injectable delivery by healthcare professionals.
• Difficult-to-match release kinetics.
• Formulation and process interdependence.
• Product-specific manufacturing know-how.
• Limited substitutability of excipient grades.
• Potential device and packaging claims.

Weakness factors include:

• Expiration of individual formulation patents.
• Potential design-around using a different depot platform.
• The ability to challenge validity or claim construction.
• The possibility of an alternative label avoiding certain method-of-use claims.
• Public availability of PLG and NMP as established excipients.

The estate should therefore be assessed as a layered formulation and platform portfolio. A single patent expiration would not necessarily eliminate all commercial barriers.

What is the revenue exposure and market opportunity?

Sublocade is one of Indivior’s principal growth products. Indivior reported Sublocade net revenue of approximately $746 million in 2023, reflecting expansion in the U.S. opioid-use-disorder market and increased use of long-acting treatment.[4]

Revenue exposure is concentrated in:

• U.S. reimbursement.
• Office-based treatment capacity.
• Medicaid and commercial-payer coverage.
• Product access and prior authorization.
• Provider willingness to administer injections.
• Supply of sterile prefilled syringes.
• Competitive long-acting buprenorphine products.

For excipient companies, the addressable opportunity is not limited to Sublocade volumes. The same polymer, solvent, device, and analytical capabilities can support long-acting formulations of other peptides, small molecules, hormones, antipsychotics, and addiction-treatment products.

Key Takeaways

• Sublocade’s commercial differentiation comes from the ATRIGEL PLG/NMP depot system, not from buprenorphine alone.
• PLG quality, molecular-weight control, solvent behavior, and depot morphology are central excipient variables.
• The strongest supplier opportunity is pharmaceutical-grade PLG supported by robust regulatory documentation.
• Solvent replacement and smaller-volume formulations offer high value but carry substantial clinical and CMC risk.
• Sublocade is a small-molecule drug, so biosimilar pathways do not apply.
• Generic entry would likely require complex formulation, pharmacokinetic, device, and sterile-manufacturing work.
• Orange Book-listed formulation and delivery patents are more important than ordinary buprenorphine composition patents.
• Longer-interval depots, device improvements, and alternative polymer systems are the leading lifecycle-management opportunities.
• Sublocade generated approximately $746 million in net revenue for Indivior in 2023, making supply continuity and patent timing commercially material.
• The best licensing targets are depot platforms, qualified excipient systems, analytical methods, and delivery devices.

FAQs

Can a generic use a different excipient from Sublocade?

Yes, but a materially different excipient system may complicate the ANDA pathway and require additional clinical or pharmacokinetic evidence. A different polymer or solvent can alter depot formation and drug release.

Is NMP the only solvent that can support a buprenorphine depot?

No. Other solvents or solvent blends may be technically feasible, but they must match polymer solubility, phase inversion, injectability, tissue tolerability, stability, and regulatory requirements.

Can PLG suppliers sell to a Sublocade competitor without infringing patents?

Possibly. PLG is a broadly used biodegradable polymer, but the specific formulation, polymer characteristics, processing conditions, and use claims require a product-specific freedom-to-operate analysis.

Would a six-month buprenorphine injection compete directly with Sublocade?

Yes. A six-month product could compete on administration frequency and adherence. It would likely require independent clinical, formulation, dosing, and intellectual-property development.

Are excipient patents alone sufficient to block a competing long-acting injection?

Usually not. Strong protection generally comes from a combination of formulation claims, process claims, method-of-use claims, device protection, manufacturing know-how, and regulatory exclusivity.

References

1. U.S. Food and Drug Administration. (2024). Sublocade (buprenorphine extended-release) injection: Prescribing information. FDA.

2. Atrion Pharmaceuticals, LLC. (n.d.). ATRIGEL drug delivery technology. Atrion Pharmaceuticals.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Indivior PLC. (2024). Annual report and accounts 2023. Indivior PLC.